Short Interest in Iradimed Corporation (NASDAQ:IRMD) Rises By 18.2%

Iradimed Corporation (NASDAQ:IRMD) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 124,100 shares, a growth of 18.2% from the December 15th total of 105,000 shares. Currently, 1.6% of the company’s shares are short sold. Based on an average daily trading volume, of 39,400 shares, the short-interest ratio is presently 3.1 days.

Iradimed Stock Performance

Iradimed stock traded up $0.81 during mid-day trading on Friday, hitting $59.17. The company’s stock had a trading volume of 50,168 shares, compared to its average volume of 37,022. The company has a 50 day moving average of $54.76 and a 200-day moving average of $50.17. Iradimed has a one year low of $40.18 and a one year high of $59.31. The stock has a market cap of $749.68 million, a PE ratio of 40.53 and a beta of 0.81.

Iradimed Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Friday, November 15th were issued a dividend of $0.15 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.60 dividend on an annualized basis and a yield of 1.01%. Iradimed’s payout ratio is 41.10%.

Insider Activity at Iradimed

In other news, CFO John Glenn sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $54.18, for a total transaction of $135,450.00. Following the transaction, the chief financial officer now owns 4,383 shares of the company’s stock, valued at approximately $237,470.94. This represents a 36.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 37.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Iradimed

Several large investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. grew its position in shares of Iradimed by 189.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 66,632 shares of the medical equipment provider’s stock worth $3,351,000 after buying an additional 43,635 shares in the last quarter. Eagle Asset Management Inc. bought a new position in Iradimed during the 3rd quarter worth about $1,239,000. Allspring Global Investments Holdings LLC increased its position in Iradimed by 14.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 20,122 shares of the medical equipment provider’s stock valued at $1,012,000 after purchasing an additional 2,538 shares during the period. Barclays PLC raised its holdings in shares of Iradimed by 113.9% in the 3rd quarter. Barclays PLC now owns 23,774 shares of the medical equipment provider’s stock valued at $1,196,000 after purchasing an additional 12,657 shares in the last quarter. Finally, Albert D Mason Inc. purchased a new stake in shares of Iradimed in the 3rd quarter worth approximately $737,000. 92.34% of the stock is owned by hedge funds and other institutional investors.

About Iradimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.